The report covers emerging HER2-Positive Breast Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current HER2-Positive Breast Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
HER2-Positive Breast Cancer: An Overview
HER2-Positive Breast Cancer is a type of breast cancer in which breast cancer cells test shows positive status for a protein receptor called human epidermal growth factor receptor 2. The normal function of this protein is to control how a healthy breast cell grows, divides, and repairs itself.
But when there is a mutation in the gene that controls the HER2 protein, also known as erythroblastic oncogene B (ERBB2) gene, the body creates too many HER2 receptors, which results in uncontrollable breast cell growth and division. The most common signs of this indication are breast swelling, change in the shape of the breast, skin irritation or dimpling, pain in the breast, and redness or thickness of the breast skin.
HER2-positive breast cancer is the second most normal cancer on the planet and the most widely recognized cancer in ladies around the world. Around 1 of 5 breast cancers are HER2-positive. Breast cancers that are HER2-positive are more forceful than different sorts of breast cancer.
Treatment for HER2-positive breast cancer depends on the tumor’s size. Patients with tumors smaller than 2 centimeters, with no lymph nodes affected, will undergo surgery first, followed by chemotherapy and a single antibody targeting the HER2 protein known as trastuzumab (Herceptin). If a tumor is larger than 2 centimeters and has spread to nearby lymph nodes, patients will receive one or two types of chemotherapy combined with two antibodies (trastuzumab plus a newer one known as pertuzumab or Perjeta). After chemotherapy, patients will undergo surgery to remove any remaining cancer cells. Patients will also receive “maintenance” antibody treatment again for a few months to help keep cancer cells from growing back. HER2 antibody therapy can sometimes cause fevers and chills during the infusion, and in rare cases, it can cause weakness of the heart muscle, also known as cardiomyopathy.
HER2-Positive Breast Cancer Market Key Facts
-
According to SEER, the incidence rate of new breast cancer cases for HR+/HER2+ is 13.4 cases per 100,000 women, as compared to the 5.5 cases per 100,000 women for HR-/HER2+ breast cancer.
-
According to the American Institute for Cancer Research, there were over 2 million new cases of breast cancer in 2018 worldwide. The age-standardized rate of breast cancer in women in the United Kingdom alone is 93.6 per 100,000.
-
As per a study conducted by Howlader et al. titled “US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status”, among case patients with known HR/HER2 status, 5240 (10.3%) were found to be HR-positive/HER2-positive and 2328 (4.6%) were HR−negative/HER2-positive.
HER2-Positive Breast Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging HER2-Positive Breast Cancer pipeline therapies. It also thoroughly assesses the HER2-Positive Breast Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed HER2-Positive Breast Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
HER2-Positive Breast Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted HER2-Positive Breast Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted HER2-Positive Breast Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the HER2-Positive Breast Cancer Epidemiology, Segmented as –
-
Total Incident Cases of Breast Cancers in the 7MM (2019-32)
-
HER2+ Incident Cases of Breast Cancer in the 7MM (2019-32)
-
Subtype-specific Incidence of Breast Cancer (HR+/HER2+ and HR-/HER2+) in the 7MM (2019-32)
-
Stage-specific Incidence of HER2+ Breast Cancer in the 7MM (2019-32)
-
Diagnosed and Treatable cases of HER2+ Breast Cancer in the 7MM (2019-32)
HER2-Positive Breast Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the HER2-Positive Breast Cancer market or expected to be launched during the study period. The analysis covers the HER2-Positive Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the HER2-Positive Breast Cancer drugs based on their sale and market share.
The report also covers the HER2-Positive Breast Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key HER2-Positive Breast Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the HER2-Positive Breast Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-market
HER2-Positive Breast Cancer Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for HER2 Positive Breast Cancer. Currently, Ambrx is leading the therapeutics market with its HER2 Positive Breast Cancer drug candidates in the most advanced stage of clinical development.
HER2-Positive Breast Cancer Companies Actively Working in the Therapeutics Market Include
-
Ambrx
-
Alteogen
-
Genentech
-
Suzhou Zanrong Pharma Limited
-
AstraZeneca
-
Shanghai Henlius Biotech
-
Roche Pharma AG
-
GeneQuantum Healthcare (Suzhou) Co., Ltd.
-
Klus Pharma Inc.
-
Carisma Therapeutics Inc
-
Triumvira Immunologics, Inc.
-
Precirix
-
DualityBio Inc.
-
Seagen Inc.
And Many Others
Emerging and Marketed HER2-Positive Breast Cancer Therapies Covered in the Report Include:
-
ALT P7: Alteogen
-
ARX 788: Ambrx
-
Inavolisib: Genentech
-
HERCEPTIN (trastuzumab): Genetech
-
PERJETA (pertuzumab): Genetech/Roche
-
SYD985 (Trastuzumab duocarmazine): Byondis.
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. HER2-Positive Breast Cancer Competitive Intelligence Analysis
4. HER2-Positive Breast Cancer Market Overview at a Glance
5. HER2-Positive Breast Cancer Disease Background and Overview
6. HER2-Positive Breast Cancer Patient Journey
7. HER2-Positive Breast Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. HER2-Positive Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. HER2-Positive Breast Cancer Unmet Needs
10. Key Endpoints of HER2-Positive Breast Cancer Treatment
11. HER2-Positive Breast Cancer Marketed Therapies
12. HER2-Positive Breast Cancer Emerging Drugs and Latest Therapeutic Advances
13. HER2-Positive Breast Cancer Seven Major Market Analysis
14. Attribute Analysis
15. HER2-Positive Breast Cancer Market Outlook (In US, EU5, and Japan)
16. HER2-Positive Breast Cancer Companies Active in the Market
17. HER2-Positive Breast Cancer Access and Reimbursement Overview
18. KOL Views on the HER2-Positive Breast Cancer Market
19. HER2-Positive Breast Cancer Market Drivers
20. HER2-Positive Breast Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Gastroesophageal Reflux Disease (GERD) Market
“Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Gastroesophageal Reflux Disease (GERD) market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/